Good morning, everyone, and how are you today? We are doing just fine, thank you, despite persistently soggy and gloomy skies hovering over the Pharmalot campus. As the Morning Mayor used to say: “Every brand new day should be unwrapped like a precious gift.” So while you tug on the ribbon and ponder the possibilities, we will brew another cup of stimulation and proceed with our usual routine of foraging for interesting items. Speaking of which, here are a few tidbits to get you going. Have a smashing day and do keep in touch. …

A coalition of pharmaceutical industry critics is accusing the largest drug makers of hiding behind research and development “as an excuse for price-gouging American patients,” STAT writes. And they cite a new study that finds drug makers spent about 22% of their revenues on research and development in 2017 to prove their point. The study, commissioned by the Campaign for Sustainable Rx Pricing, was based largely on analysis of 2017 Security and Exchange Commission filings for the 10 largest U.S.-based drug makers that generate more than half their revenue from medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • One wonders how much of the 340B increase is due to the increase in the base cost of the purchased product? That is an area that the article does not address, while it does seem to make a case that the absolute growth as opposed to the manufacturers net should be troubling.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy